Last updated: October 31, 2026
GAMMAPLEX is a human intravenous immunoglobulin product supplied by Bio Products Laboratory Ltd. (BPL), now part of Kedrion Biopharma. Its commercial position is supported by recurring demand for immune globulin, physician familiarity, and the manufacturing barriers associated with plasma-derived biologics. Its financial trajectory cannot be isolated from public filings because Kedrion is privately held and does not report GAMMAPLEX revenue separately.
The principal risks are supply dependence on recovered plasma, competition from other IVIG brands, hospital and specialty-pharmacy purchasing pressure, and the possibility of biosimilar competition after biologic exclusivity has expired. Generic substitution through an ANDA is not available for GAMMAPLEX.
What is GAMMAPLEX and who manufactures it?
GAMMAPLEX is an intravenous immune globulin, human, made from pooled human plasma. It is marketed in the United States by BPL and manufactured within BPL’s plasma-derived product network. Kedrion acquired BPL in 2022, creating a larger plasma-products platform with operations spanning plasma collection, fractionation, purification and commercialization. [1]
| Attribute |
GAMMAPLEX |
| Active ingredient |
Immune globulin intravenous, human |
| Product class |
Plasma-derived biologic |
| Primary dosage forms |
5% and 10% intravenous solutions |
| U.S. regulatory pathway |
Biologics license application |
| Manufacturer and sponsor history |
BPL; BPL became part of Kedrion Biopharma |
| Core indications |
Primary humoral immunodeficiency and chronic immune thrombocytopenic purpura, depending on presentation and labeling |
| Substitution pathway |
No conventional ANDA generic pathway |
| Biosimilar pathway |
Potential 351(k) pathway |
| Public standalone revenue |
Not disclosed |
GAMMAPLEX competes in the same broad IVIG category as GAMUNEX-C, Privigen, Gammagard Liquid, Octagam, Panzyga and Flebogamma. Product-level differentiation is limited because most products deliver pooled IgG, but clinical familiarity, purity profile, infusion tolerability, supply reliability, contracting and reimbursement determine purchasing decisions.
What FDA indications does GAMMAPLEX have?
GAMMAPLEX has been approved for replacement therapy in primary immunodeficiency and for treatment of chronic immune thrombocytopenic purpura in adults, subject to the specific product presentation and current FDA labeling. [2]
Primary immunodeficiency
The primary immunodeficiency market produces recurring demand because patients generally require repeated infusions over long treatment periods. This creates a more predictable volume base than acute-use indications.
Treatment frequency varies by patient, clinical response, body weight and payer authorization. Demand is therefore linked to the diagnosed patient population and treatment intensity rather than only to new prescriptions.
Chronic immune thrombocytopenic purpura
The ITP indication is more episodic. IVIG can be used when a rapid increase in platelet count is clinically required, including before procedures or during significant bleeding risk. This market contributes to utilization but is less predictable than long-term replacement therapy.
When does GAMMAPLEX lose exclusivity?
GAMMAPLEX’s U.S. biologic exclusivity period has expired.
FDA approved GAMMAPLEX in 2010. Under the Biologics Price Competition and Innovation Act, a reference biologic receives 12 years of reference-product exclusivity from first licensure, subject to statutory rules governing first licensure and patent certifications. The practical reference-product exclusivity period therefore ended around 2022. [3]
| Milestone |
Approximate timing |
| FDA approval of GAMMAPLEX |
2010 |
| Twelve-year reference-product exclusivity |
Approximately 2022 |
| Current status |
Post-exclusivity biologic |
| ANDA generic entry |
Not available |
| 351(k) biosimilar entry |
Legally available, subject to FDA approval and commercial litigation |
Expiration of regulatory exclusivity does not guarantee near-term competition. IVIG manufacturing requires qualified plasma supply, validated fractionation capacity, viral-clearance controls, extensive comparability data and specialized distribution. These requirements create higher entry barriers than those associated with conventional small-molecule generics.
What is the Orange Book status of GAMMAPLEX?
GAMMAPLEX is not an Orange Book small-molecule product. The FDA’s Orange Book primarily covers approved drug products and their associated patents under the Hatch-Waxman framework. Biologic reference products are tracked through FDA biologics records and the Purple Book rather than through a standard Orange Book patent-listing structure. [4]
This distinction has several commercial consequences:
- A competitor cannot file a standard ANDA seeking automatic substitution for GAMMAPLEX.
- A biosimilar applicant generally uses the Public Health Service Act section 351(k) pathway.
- Patent disclosures, litigation and market-entry timing follow the BPCIA framework rather than ordinary Paragraph IV procedures.
- Pharmacy substitution depends on FDA interchangeability determinations and state law, not simply on generic-equivalence status.
Are there Paragraph IV challenges to GAMMAPLEX?
No material, publicly established Paragraph IV challenge is associated with GAMMAPLEX’s U.S. approval because GAMMAPLEX is a biologic rather than an ANDA-eligible small-molecule drug.
A biosimilar applicant would instead participate in the BPCIA patent-information exchange and related litigation process. Publicly available information does not identify a major announced GAMMAPLEX biosimilar litigation campaign or a marketed FDA-approved GAMMAPLEX biosimilar.
What litigation affects GAMMAPLEX?
No major publicly documented U.S. patent litigation campaign involving GAMMAPLEX is identified in the principal public regulatory and corporate sources reviewed for this analysis. The absence of disclosed litigation does not eliminate potential process, formulation, manufacturing or trade-secret disputes, but it indicates no visible litigation-driven near-term launch event.
How strong is the GAMMAPLEX patent estate?
The commercial defensibility of GAMMAPLEX appears to rest more heavily on manufacturing capability, regulatory compliance, plasma access and customer relationships than on a publicly prominent patent estate.
Formulation patents
GAMMAPLEX’s value is not dependent solely on a single formulation claim. IVIG products can be protected by patents directed to:
- Stabilizer systems and excipients
- Protein concentration and solution characteristics
- Viral inactivation and removal
- Purification and fractionation processes
- Container and delivery systems
- Manufacturing controls and quality attributes
Publicly visible market information does not establish a currently decisive, GAMMAPLEX-specific U.S. formulation patent blocking biosimilar entry. A biosimilar applicant would still need to evaluate BPL and Kedrion patents, manufacturing patents, process know-how and potential regulatory exclusivity issues.
Method-of-use patents
The core GAMMAPLEX indications are established therapeutic uses rather than a clearly disclosed late-life-cycle method-of-use strategy. Method-of-use patents, where enforceable, could affect particular dosing regimens or patient subgroups, but they would not necessarily prevent a biosimilar from entering for non-patented indications.
Manufacturing and trade-secret barriers
Manufacturing barriers are more important than conventional patent protection in the IVIG market. Relevant barriers include:
- Access to qualified human plasma.
- Large-scale fractionation and purification capacity.
- Viral safety and pathogen-reduction validation.
- Batch-to-batch consistency for pooled plasma products.
- FDA inspection history and compliance systems.
- Cold-chain logistics and specialty distribution.
- Pharmacovigilance and post-market quality controls.
These barriers can delay or discourage entry even after patent and exclusivity rights expire.
Which companies compete with GAMMAPLEX?
GAMMAPLEX competes in a concentrated global IVIG market. Major competitors include products from Grifols, CSL Behring, Takeda, Octapharma, Pfizer, Kedrion and other plasma-product companies.
| Product |
Company |
Competitive relevance |
| GAMUNEX-C |
Grifols |
Large U.S. IVIG franchise with broad provider familiarity |
| Privigen |
CSL Behring |
Major liquid IVIG product with extensive specialty distribution |
| Gammagard Liquid |
Takeda |
Established IVIG brand with strong immunology presence |
| Octagam |
Octapharma |
Competes across replacement and immunomodulatory uses |
| Panzyga |
Pfizer |
Established IVIG competitor with U.S. commercialization |
| Flebogamma DIF |
Grifols |
Global plasma-derived immunoglobulin brand |
| GAMMAPLEX |
BPL/Kedrion |
Smaller commercial position relative to the largest multinational IVIG brands |
The competitive basis is primarily supply availability, contract terms, hospital formulary position, infusion-center experience and payer coverage. Clinical differentiation exists, but it is usually less decisive than dependable supply and total treatment economics.
What market dynamics are driving GAMMAPLEX sales?
The IVIG market has durable demand but recurring supply constraints.
Plasma supply
Plasma is the limiting input for most IVIG products. Collection volumes depend on donor recruitment, center operations, compensation, regulatory requirements and geographic restrictions. A disruption in plasma collection can affect product availability months later because fractionation and release cycles are lengthy.
Kedrion’s ownership of BPL gives GAMMAPLEX access to a broader corporate platform than BPL had as a standalone supplier. The commercial benefit depends on how Kedrion allocates plasma, production slots and sales resources among its products.
Demand growth
Demand is supported by:
- Greater diagnosis of primary immunodeficiency.
- Aging populations and increased use of immunomodulatory therapy.
- Expanded physician familiarity with IVIG.
- Chronic use in selected neurologic, hematologic and immunologic disorders.
- Continued treatment of patients who are poor candidates for alternative therapies.
Demand can also be reduced by payer controls, subcutaneous immunoglobulin conversion and efforts to reserve IVIG for evidence-supported indications.
Pricing and reimbursement
IVIG pricing is shaped by acquisition cost, dose, site of care, payer contracting, handling fees and administration economics. Hospitals and specialty distributors may accept a product with lower price or better supply terms even when several clinically similar IVIG products are available.
GAMMAPLEX’s financial performance is therefore likely to reflect net price and volume after rebates rather than list price alone. Public sources do not disclose brand-level net pricing.
What is GAMMAPLEX’s financial trajectory?
Standalone GAMMAPLEX revenue is not publicly reported. Kedrion is privately held, and BPL financial disclosures do not provide a consistent, detailed U.S. brand-level revenue series for GAMMAPLEX.
The most defensible financial assessment is directional:
| Period |
Financial interpretation |
| 2010-2018 |
Established product phase, supported by FDA approval and recurring IVIG demand |
| 2019-2021 |
Mature-brand phase with exposure to plasma supply, reimbursement and competitive pressure |
| 2022 |
Ownership transition into Kedrion; potential benefits from broader operational scale |
| 2023 onward |
Post-exclusivity period; revenue depends on supply execution, contracting and biosimilar defense |
| Medium term |
Stable or modest-growth potential in a growing IVIG category, offset by pricing and input-cost pressure |
GAMMAPLEX is unlikely to be a major disclosed earnings driver on the scale of the largest global IVIG brands. Its strategic value is more likely tied to portfolio breadth, manufacturing utilization and customer retention within Kedrion’s plasma-derived business.
What generic or biosimilar launch risks exist?
The immediate generic-launch risk is low because ANDA substitution is unavailable. The relevant risk is biosimilar competition.
Biosimilar risk factors
A potential GAMMAPLEX biosimilar competitor would face:
- Clinical and analytical comparability requirements.
- Reference-product sourcing and characterization.
- Manufacturing scale-up.
- Plasma procurement and donor-network requirements.
- FDA inspection and release controls.
- Potential BPCIA patent disputes.
- Contracting against established IVIG brands.
- The need to secure payer and provider adoption.
The risk is therefore better characterized as medium-term strategic erosion rather than an imminent automatic substitution event.
A biosimilar could still pressure GAMMAPLEX through hospital tenders, specialty-distributor contracting and payer preference even without an interchangeability designation. The commercial impact would depend on whether the entrant has sufficient plasma capacity and whether it can offer reliable supply at a meaningful discount.
How does GAMMAPLEX compare with competing IVIG products?
GAMMAPLEX has the standard strengths and weaknesses of a mature IVIG brand.
| Factor |
GAMMAPLEX position |
| Clinical demand |
Supported by recurring primary immunodeficiency use |
| Regulatory maturity |
Long-established FDA-approved product |
| Patent exclusivity |
No longer the primary barrier |
| Manufacturing barrier |
Significant because of plasma and fractionation requirements |
| Brand scale |
Smaller than leading global IVIG franchises |
| Supply leverage |
Improved by Kedrion ownership, but dependent on network capacity |
| Biosimilar exposure |
Possible, but entry is difficult |
| Switching risk |
Moderate where payers or providers prioritize cost |
| Price sensitivity |
High in institutional and distributor channels |
| Revenue transparency |
Low because standalone product sales are not disclosed |
What are the key commercial scenarios for GAMMAPLEX?
Base case
GAMMAPLEX maintains a stable position in the IVIG market, with volume supported by recurring immunodeficiency demand. Revenue grows modestly with category demand but faces pricing pressure and costs associated with plasma procurement.
Upside case
Kedrion improves supply reliability, expands contracting coverage and uses its broader portfolio to increase provider access. GAMMAPLEX gains share in accounts seeking a dependable secondary or alternative IVIG supplier.
Downside case
Plasma shortages, manufacturing interruptions, payer exclusion or aggressive competitor contracting reduce volume. A biosimilar or lower-cost IVIG entrant increases price pressure after establishing reliable supply.
Key Takeaways
- GAMMAPLEX is a plasma-derived IVIG product originally developed and commercialized by BPL.
- BPL became part of Kedrion Biopharma in 2022.
- FDA reference-product exclusivity has expired, but conventional generic substitution is unavailable.
- No material Paragraph IV challenge is expected because GAMMAPLEX is regulated as a biologic.
- Biosimilar competition is legally possible but operationally difficult.
- The product’s most important defenses are plasma access, manufacturing capacity, regulatory compliance and supply reliability.
- Kedrion does not publicly disclose standalone GAMMAPLEX revenue.
- Financial performance is likely to be stable or modestly growing at the category level, with pressure from procurement costs, payer negotiations and competing IVIG products.
- The main investment and licensing question is not whether GAMMAPLEX has long patent life. It is whether Kedrion can maintain competitive supply and contracting economics in a capacity-constrained IVIG market.
FAQs
Is GAMMAPLEX interchangeable with other IVIG products?
No. IVIG products are not automatically interchangeable merely because they contain human immunoglobulin. Substitution depends on product-specific regulatory status, prescriber decisions, payer rules and applicable state law.
Can a company launch a generic version of GAMMAPLEX?
No conventional ANDA generic can be approved for GAMMAPLEX. A competing company would generally need to pursue the FDA’s 351(k) biosimilar pathway or submit a separate biologics license application.
Does Kedrion report GAMMAPLEX sales separately?
No publicly available Kedrion reporting provides a reliable standalone GAMMAPLEX revenue figure. Kedrion is privately held, and product-level revenue is not reported in the detail required for a verified financial time series.
Is GAMMAPLEX exposed to subcutaneous immunoglobulin competition?
Yes. Subcutaneous immunoglobulin can replace IVIG for selected patients, especially in chronic replacement therapy. The substitution risk is lower in acute immunomodulatory uses where intravenous administration is clinically preferred.
What is the largest long-term risk to GAMMAPLEX value?
The largest long-term risk is a combination of plasma-supply disruption and contracting pressure from larger IVIG suppliers. Biosimilar entry is a secondary risk because manufacturing and supply requirements make rapid market penetration difficult.
References
- Kedrion Biopharma. (2022). Kedrion Biopharma completes acquisition of Bio Products Laboratory. https://www.kedrion.com
- U.S. Food and Drug Administration. (2024). GAMMAPLEX prescribing information. Bio Products Laboratory. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2024). Biologics Price Competition and Innovation Act: Reference product exclusivity. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov